• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by AbCellera Biologics Inc. (Amendment)

    2/14/22 3:24:07 PM ET
    $ABCL
    Pharmaceuticals and Biotechnology
    Health Care
    Get the next $ABCL alert in real time by email
    SC 13G/A 1 tm226145d3_sc13ga.htm SC 13G/A

     

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Schedule 13G

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b)

    (Amendment No. 1) *

     

    AbCellera Biologics Inc.

    (Name of Issuer)

     

    Common Shares, no par value per share

    (Title of Class of Securities)

     

    00288U106

    (CUSIP Number)

     

    December 31, 2021

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    x Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    (Continued on following pages)

     

    Page 1 of 17 Pages

    Exhibit Index Contained on Page 16

     

     

     

     

     

     

    CUSIP NO. 00288U106  13G  Page 2 of 17

     

    1 NAME OF REPORTING PERSON          DCVC Bio, L.P. (“DCVC Bio”)
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a)          ¨         (b)          x          

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware

     

    NUMBER OF

     

    SHARES

     

    BENEFICIALLY

     

    OWNED BY EACH

     

    REPORTING

     

    PERSON

     

    WITH

    5 SOLE VOTING POWER
    7,305,761 shares, except that DCVC Bio GP, LLC (“DCVC Bio GP”), the general partner of DCVC Bio, may be deemed to have sole voting power with respect to such shares, JNK Capital Management, LLC (“JNK”), a managing member of DCVC Bio GP, may be deemed to have shared voting power with respect to such shares, ZNM Capital Management, LLC (“ZNM”), a managing member of DCVC Bio GP, may be deemed to have shared voting power with respect to such shares, and Kiersten Stead (“Stead”) and John Hamer (“Hamer”), the managing members of JNK, and Zachary Bogue (“Bogue”) and Matthew Ocko (“Ocko”), the managing members of ZNM, may be deemed to have shared voting power with respect to such shares.
    6 SHARED VOTING POWER
    See response to row 5.
    7 SOLE DISPOSITIVE POWER
    7,305,761 shares, except that DCVC Bio GP, the general partner of DCVC Bio, may be deemed to have sole dispositive power with respect to such shares, JNK, a managing member of DCVC Bio GP, may be deemed to have shared dispositive power with respect to such shares, ZNM, a managing member of DCVC Bio GP, may be deemed to have shared dispositive power with respect to such shares, and Stead and Hamer, the managing members of JNK, and Bogue and Ocko, the managing members of ZNM, may be deemed to have shared dispositive power with respect to such shares.
    8 SHARED DISPOSITIVE POWER
    See response to row 7.

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 7,305,761
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW 9 EXCLUDES CERTAIN SHARES* ¨               
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 2.6%
    12 TYPE OF REPORTING PERSON* PN

     

     

     

     

    CUSIP NO. 00288U106  13G  Page 3 of 17

     

    1 NAME OF REPORTING PERSON          DCVC Bio GP, LLC (“DCVC Bio GP”)
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a)          ¨         (b)          x          

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware

     

    NUMBER OF

     

    SHARES

     

    BENEFICIALLY

     

    OWNED BY EACH

     

    REPORTING

     

    PERSON

     

    WITH

    5 SOLE VOTING POWER
    7,305,761 shares, all of which are held by DCVC Bio, L.P. (“DCVC Bio”), for whom DCVC Bio GP serves as general partner, except that JNK Capital Management, LLC (“JNK”), a managing member of DCVC Bio GP, may be deemed to have shared voting power with respect to such shares, ZNM Capital Management, LLC (“ZNM”), a managing member of DCVC Bio GP, may be deemed to have shared voting power with respect to such shares, and Kiersten Stead (“Stead”) and John Hamer (“Hamer”), the managing members of JNK, and Zachary Bogue (“Bogue”) and Matthew Ocko (“Ocko”), the managing members of ZNM, may be deemed to have shared voting power with respect to such shares.
    6 SHARED VOTING POWER
    See response to row 5.
    7 SOLE DISPOSITIVE POWER
    7,305,761 shares, all of which are held by DCVC Bio, for whom DCVC Bio GP serves as general partner, except that JNK, a managing member of DCVC Bio GP, may be deemed to have shared dispositive power with respect to such shares, ZNM, a managing member of DCVC Bio GP, may be deemed to have shared dispositive power with respect to such shares, and Stead and Hamer, the managing members of JNK, and Bogue and Ocko, the managing members of ZNM, may be deemed to have shared dispositive power with respect to such shares.
    8 SHARED DISPOSITIVE POWER
    See response to row 7.

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 7,305,761
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* ¨               
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 2.6%
    12 TYPE OF REPORTING PERSON* OO

     

     

     

     

    CUSIP NO. 00288U106  13G  Page 4 of 17

     

    1 NAME OF REPORTING PERSON          JNK Capital Management, LLC (“JNK”)
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a)          ¨         (b)          x          

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware

     

    NUMBER OF

     

    SHARES

     

    BENEFICIALLY

     

    OWNED BY EACH

     

    REPORTING

     

    PERSON

     

    WITH

    5 SOLE VOTING POWER
    0 shares.
    6 SHARED VOTING POWER
    7,305,761 shares, all of which are held by DCVC Bio, L.P. (“DCVC Bio”). JNK serves as a managing member of DCVC Bio GP, LLC (“DCVC Bio GP”), the general partner of DCVC Bio, and may be deemed to have shared voting power with respect to such shares. Kiersten Stead (“Stead”) and John Hamer (“Hamer”), the managing members of JNK, may be deemed to have shared voting power with respect to such shares.
    7 SOLE DISPOSITIVE POWER
    0 shares.
    8 SHARED DISPOSITIVE POWER
    7,305,761 shares, all of which are held by DCVC Bio. JNK serves as a managing member of DCVC Bio GP, the general partner of DCVC Bio, and may be deemed to have shared dispositive power with respect to such shares. Stead and Hamer, the managing members of JNK, may be deemed to have shared dispositive power with respect to such shares.

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 7,305,761
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* ¨               
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 2.6%
    12 TYPE OF REPORTING PERSON* OO

     

     

     

     

    CUSIP NO. 00288U106  13G  Page 5 of 17

     

    1 NAME OF REPORTING PERSON          ZNM Capital Management, LLC (“ZNM”)
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a)          ¨         (b)          x          

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware

     

    NUMBER OF

     

    SHARES

     

    BENEFICIALLY

     

    OWNED BY EACH

     

    REPORTING

     

    PERSON

     

    WITH

    5 SOLE VOTING POWER
    0 shares.
    6 SHARED VOTING POWER
    7,305,761 shares, all of which are held by DCVC Bio, L.P. (“DCVC Bio”). ZNM serves as a managing member of DCVC Bio GP (“DCVC Bio GP”), the general partner of DCVC Bio, and may be deemed to have shared voting power with respect to such shares. Zachary Bogue (“Bogue”) and Matthew Ocko (“Ocko”), the managing members of ZNM, may be deemed to have shared voting power with respect to such shares.
    7 SOLE DISPOSITIVE POWER
    0 shares.
    8 SHARED DISPOSITIVE POWER
    7,305,761 shares, all of which are held by DCVC Bio. ZNM serves as a managing member of DCVC Bio GP, the general partner of DCVC Bio, and may be deemed to have shared dispositive power with respect to such shares. Bogue and Ocko, the managing members of ZNM, may be deemed to have shared dispositive power with respect to such shares.

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 7,305,761
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* ¨               
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 2.6%
    12 TYPE OF REPORTING PERSON* OO

     

     

     

     

    CUSIP NO. 00288U106  13G  Page 6 of 17

     

    1 NAME OF REPORTING PERSON          Zachary Bogue (“Bogue”)
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a)          ¨         (b)          x          

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    U.S. Citizen

     

    NUMBER OF

     

    SHARES

     

    BENEFICIALLY

     

    OWNED BY EACH

     

    REPORTING

     

    PERSON

     

    WITH

    5 SOLE VOTING POWER
    0 shares
    6 SHARED VOTING POWER
    7,305,761 shares, all of which are held by DCVC Bio, L.P. (“DCVC Bio”). DCVC Bio GP (“DCVC Bio GP”) is the general partner of DCVC Bio and Bogue, as a managing member of ZNM Capital Management, LLC (“ZNM”), a managing member of DCVC Bio GP, may be deemed to have shared voting power with respect to such shares.
    7 SOLE DISPOSITIVE POWER
    0 shares
    8 SHARED DISPOSITIVE POWER
    7,305,761 shares, all of which are held by DCVC Bio. DCVC Bio GP is the general partner of DCVC Bio and Bogue, as a managing member of ZNM, a managing member of DCVC Bio GP, may be deemed to have shared dispositive power with respect to such shares.

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 7,305,761
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* ¨               
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 2.6%
    12 TYPE OF REPORTING PERSON* IN

     

     

     

     

    CUSIP NO. 00288U106  13G  Page 7 of 17

     

    1 NAME OF REPORTING PERSON          Matthew Ocko (“Ocko”)
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a)          ¨         (b)          x          

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    U.S. Citizen

     

    NUMBER OF

     

    SHARES

     

    BENEFICIALLY

     

    OWNED BY EACH

     

    REPORTING

     

    PERSON

     

    WITH

    5 SOLE VOTING POWER
    0 shares
    6 SHARED VOTING POWER
    7,305,761 shares, all of which are held by DCVC Bio, L.P. (“DCVC Bio”). DCVC Bio GP (“DCVC Bio GP”) is the general partner of DCVC Bio and Ocko, as a managing member of ZNM Capital Management, LLC (“ZNM”), a managing member of DCVC Bio GP, may be deemed to have shared voting power with respect to such shares.
    7 SOLE DISPOSITIVE POWER
    0 shares
    8 SHARED DISPOSITIVE POWER
    7,305,761 shares, all of which are held by DCVC Bio. DCVC Bio GP is the general partner of DCVC Bio and Ocko, as a managing member of ZNM, a managing member of DCVC Bio GP, may be deemed to have shared dispositive power with respect to such shares.

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 7,305,761
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* ¨               
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 2.6%
    12 TYPE OF REPORTING PERSON* IN

     

     

     

     

    CUSIP NO. 00288U106  13G  Page 8 of 17

     

    1 NAME OF REPORTING PERSON          Kiersten Stead (“Stead”)
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a)          ¨         (b)          x          

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    U.S. Citizen

     

    NUMBER OF

     

    SHARES

     

    BENEFICIALLY

     

    OWNED BY EACH

     

    REPORTING

     

    PERSON

     

    WITH

    5 SOLE VOTING POWER
    0 shares
    6 SHARED VOTING POWER
    7,305,761 shares, all of which are held by DCVC Bio, L.P. (“DCVC Bio”). DCVC Bio GP (“DCVC Bio GP”) is the general partner of DCVC Bio and Stead, as a managing member of JNK Capital Management, LLC (“JNK”), a managing member of DCVC Bio GP, may be deemed to have shared voting power with respect to such shares.
    7 SOLE DISPOSITIVE POWER
    0 shares
    8 SHARED DISPOSITIVE POWER
    7,305,761 shares, all of which are held by DCVC Bio. DCVC Bio GP is the general partner of DCVC Bio and Stead, as a managing member of JNK, a managing member of DCVC Bio GP, may be deemed to have shared dispositive power with respect to such shares.

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 7,305,761
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* ¨               
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 2.6%
    12 TYPE OF REPORTING PERSON* IN

     

     

     

     

    CUSIP NO. 00288U106  13G  Page 9 of 17

     

    1 NAME OF REPORTING PERSON          John Hamer (“Hamer”)
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a)          ¨         (b)          x          

    3 SEC USE ONLY
    4 CITIZENSHIP OR PLACE OF ORGANIZATION
    U.S. Citizen

     

    NUMBER OF

     

    SHARES

     

    BENEFICIALLY

     

    OWNED BY EACH

     

    REPORTING

     

    PERSON

     

    WITH

    5 SOLE VOTING POWER
    0 shares
    6 SHARED VOTING POWER
    7,305,761 shares, all of which are held by DCVC Bio, L.P. (“DCVC Bio”). DCVC Bio GP (“DCVC Bio GP”) is the general partner of DCVC Bio and Hamer, as a managing member of JNK Capital Management, LLC (“JNK”), a managing member of DCVC Bio GP, may be deemed to have shared voting power with respect to such shares.
    7 SOLE DISPOSITIVE POWER
    0 shares
    8 SHARED DISPOSITIVE POWER
    7,305,761 shares, all of which are held by DCVC Bio. DCVC Bio GP is the general partner of DCVC Bio and Hamer, as a managing member of JNK, a managing member of DCVC Bio GP, may be deemed to have shared dispositive power with respect to such shares.

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 7,305,761
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* ¨               
    11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 2.6%
    12 TYPE OF REPORTING PERSON* IN

     

     

     

     

    CUSIP NO. 00288U106  13G  Page 10 of 17

     

    ITEM 1(A).NAME OF ISSUER

     

    AbCellera Biologics Inc.

     

    ITEM 1(B).ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES

     

    2215 Yukon Street

    Vancouver, BC V5Y 0A1

     

    ITEM 2(A).NAME OF PERSONS FILING

     

    This Statement is filed by DCVC Bio, L.P., a Delaware limited partnership (“DCVC Bio”), DCVC Bio GP, LLC, a Delaware limited liability company (“DCVC Bio GP”), JNK Capital Management, LLC, a Delaware limited liability company (“JNK”), ZNM Capital Management, LLC, a Delaware limited liability company (“ZNM”), Zachary Bogue (“Bogue”), Matthew Ocko (“Ocko”), John Hamer (“Hamer”) and Kiersten Stead (“Stead”). The foregoing entities and individuals are collectively referred to as the “Reporting Persons.”

     

    DCVC Bio GP is the general partner of DCVC Bio, and may be deemed to have indirect beneficial ownership of shares of the issuer directly owned by DCVC Bio. ZNM is a managing member of DCVC Bio GP and may be deemed to have indirect beneficial ownership of shares of the issuer directly owned by DCVC Bio. JNK is a managing member of DCVC Bio GP and may be deemed to have indirect beneficial ownership of shares of the issuer directly owned by DCVC Bio. Bogue and Ocko are managing members of ZNM and may be deemed to have indirect beneficial ownership of shares of the issuer directly owned by DCVC Bio. Hamer and Stead are managing members of JNK and may be deemed to have indirect beneficial ownership of shares of the issuer directly owned by DCVC Bio.

     

    ITEM 2(B).ADDRESS OF PRINCIPAL OFFICE

     

    The address for each of the Reporting Persons is:

     

    270 University Avenue
    Palo Alto, CA 94301

     

    ITEM 2(C).CITIZENSHIP

     

    DCVC Bio is a Delaware limited partnership. DCVC Bio GP, JNK and ZNM are Delaware limited liability companies. Bogue, Ocko, Hamer and Stead are United States citizens.

     

    ITEM 2(D) AND (E).          TITLE OF CLASS OF SECURITIES AND CUSIP NUMBER

     

    Common Shares, no par value per share
    CUSIP # 00288U106

     

    ITEM 3.Not Applicable.

     

     

     

     

    CUSIP NO. 00288U106  13G  Page 11 of 17

     

    ITEM 4.OWNERSHIP

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a)Amount beneficially owned:

     

    See Row 9 of cover page for each Reporting Person.

     

    (b)Percent of Class:

     

    See Row 11 of cover page for each Reporting Person.

     

    (c)Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote:

     

    See Row 5 of cover page for each Reporting Person.

     

    (ii)Shared power to vote or to direct the vote:

     

    See Row 6 of cover page for each Reporting Person.

     

    (iii)Sole power to dispose or to direct the disposition of:

     

    See Row 7 of cover page for each Reporting Person.

     

    (iv)Shared power to dispose or to direct the disposition of:

     

    See Row 8 of cover page for each Reporting Person.

     

    ITEM 5.OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

     

    ITEM 6.OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

     

    Under certain circumstances set forth in the limited partnership agreement of DCVC Bio, and the limited liability company agreements of DCVC Bio GP, JNK Capital Management, LLC and ZNM Capital Management, LLC, the general and limited partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the issuer owned by each such entity of which they are a partner or member, as the case may be.

     

    ITEM 7.IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON

     

    Not applicable.

     

     

     

     

    CUSIP NO. 00288U106  13G  Page 12 of 17

     

    ITEM 8.IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP

     

    Not applicable.

     

    ITEM 9.NOTICE OF DISSOLUTION OF GROUP

     

    Not applicable.

     

    ITEM 10.CERTIFICATION

     

    Not applicable.

     

     

     

     

    CUSIP NO. 00288U106  13G  Page 13 of 17

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: February 14, 2021

     

        DCVC Bio, L.P.
         
        By:  DCVC Bio GP, LLC, its General Partner
         
        By: JNK Capital Management, LLC, its Managing Member
         
      By: /s/ John Hamer
      Name: John Hamer
      Title: Managing Member
         
      By: /s/ Kiersten Stead
      Name: Kiersten Stead
      Title: Managing Member
         
        By: ZNM Capital Management, LLC, its Managing Member
         
      By: /s/ Matthew Ocko
      Name: Matthew Ocko
      Title: Managing Member
         
      By: /s/ Zachary Bogue
      Name: Zachary Bogue
      Title: Managing Member
         
        DCVC Bio GP, LLC
         
        By: JNK Capital Management, LLC, its Managing Member
         
      By: /s/ John Hamer
      Name: John Hamer
      Title: Managing Member
         
      By: /s/ Kiersten Stead
      Name: Kiersten Stead
      Title: Managing Member
         
        By: ZNM Capital Management, LLC, its Managing Member
         
      By: /s/ Matthew Ocko
      Name: Matthew Ocko
      Title: Managing Member

     

     

     

     

    CUSIP NO. 00288U106  13G  Page 14 of 17

     

      By: /s/ Zachary Bogue
      Name: Zachary Bogue
      Title: Managing Member
         
        JNK Capital Management, LLC
         
      By: /s/ John Hamer
      Name: John Hamer
      Title: Managing Member
         
      By: /s/ Kiersten Stead
      Name: Kiersten Stead
      Title: Managing Member
         
        ZNM Capital Management, LLC
         
      By: /s/ Matthew Ocko
      Name: Matthew Ocko
      Title: Managing Member
         
      By: /s/ Zachary Bogue
      Name: Zachary Bogue
      Title: Managing Member
         
        John Hamer
         
      By: /s/ John Hamer
      Name: John Hamer
         
        Kiersten Stead
         
      By: /s/ Kiersten Stead
      Name: Kiersten Stead
         
        Matthew Ocko
         
      By: /s/ Matthew Ocko
      Name: Matthew Ocko
         
        Zachary Bogue
         
      By: /s/ Zachary Bogue
      Name: Zachary Bogue

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

     

     

     

    CUSIP NO. 00288U106  13G  Page 15 of 17

     

    NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties for whom copies are to be sent.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

     

     

     

     

    CUSIP NO. 00288U106  13G  Page 16 of 17

     

    EXHIBIT INDEX

     

      Found on
    Sequentially
    Exhibit Numbered Page
       
    Exhibit A:  Agreement of Joint Filing 17

     

     

     

     

    CUSIP NO. 00288U106  13G  Page 17 of 17

     

    exhibit A

     

    Agreement of Joint Filing

     

    The Reporting Persons hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Shares of AbCellera Biologics Inc. shall be filed on behalf of each of the Reporting Persons. Note that a copy of the applicable Agreement of Joint Filing is already on file with the appropriate agencies.

     

     

     

    Get the next $ABCL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABCL

    DatePrice TargetRatingAnalyst
    8/20/2024Buy → Hold
    The Benchmark Company
    2/22/2024$9.00Hold → Buy
    The Benchmark Company
    12/5/2023$6.00Overweight
    KeyBanc Capital Markets
    11/6/2023Buy → Hold
    The Benchmark Company
    10/13/2023$20.00Overweight
    Piper Sandler
    2/28/2023Outperform
    Cowen
    12/15/2022$30.00Buy
    Goldman
    11/16/2022$29.00Buy
    Truist
    More analyst ratings

    $ABCL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

      The Federal Circuit rejects Bruker Cellular's invalidity challenge to AbCellera's patent for microfluidic devices and their use in culturing cells AbCellera (NASDAQ:ABCL) today announced that the United States Court of Appeals for the Federal Circuit (CAFC) has by a Rule 36 Order affirmed judgment of validity of its U.S. Patent No. 10,087,408 ("the ‘408 Patent"). AbCellera's ‘408 Patent is directed to microfluidic devices and using such devices to culture and selectively recover cells. Previously Berkeley Lights Inc., now Bruker Cellular Analysis, Inc. (Bruker), a subsidiary of Bruker Corporation, challenged the claims of the ‘408 Patent alleging invalidity based on anticipation and obvio

      5/12/25 3:30:00 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

      ABCL575 is a novel, half-life extended anti-OX40L monoclonal antibody that is being developed for the treatment of moderate-to-severe atopic dermatitis (AD) In preclinical studies, ABCL575 shows potent inhibition of inflammatory pathways, favorable in vivo pharmacokinetics (PK), and potential for less frequent dosing compared to a clinical benchmark   AbCellera (NASDAQ:ABCL) today announced preclinical data on ABCL575, which will be presented as a poster at the Society for Investigative Dermatology (SID) Annual Meeting at the Hilton Bayfront in San Diego, California. AbCellera's presentation, which is available for viewing here, describes key properties of ABCL575, including: Poten

      5/9/25 7:30:00 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • AbCellera Reports Q1 2025 Business Results

      AbCellera (NASDAQ:ABCL) today announced financial results for the first quarter of 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "After completion of a successful first quarter, we are excited to introduce ABCL635 as a potential first-in-class antibody for the non-hormonal treatment of vasomotor symptoms (hot flashes) associated with menopause. ABCL635 is positioned as a next-generation neurokinin 3 receptor (NK3R) antagonist with an improved safety profile and convenient dosing regimen. If successful, we believe it has the potential to be a highly differentiated product in a large and established market," said Carl Hansen, P

      5/8/25 4:05:00 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care

    $ABCL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Thermopylae Holdings Ltd. bought $742,243 worth of shares (343,631 units at $2.16), increasing direct ownership by 0.62% to 56,143,640 units (SEC Form 4)

      4 - AbCellera Biologics Inc. (0001703057) (Issuer)

      3/11/25 6:42:57 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • Director Montalbano John S. bought $57,500 worth of shares (25,000 units at $2.30), increasing direct ownership by 17% to 171,000 units (SEC Form 4)

      4 - AbCellera Biologics Inc. (0001703057) (Issuer)

      3/10/25 5:11:03 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • Director Montalbano John S. bought $140,568 worth of shares (60,000 units at $2.34), increasing direct ownership by 70% to 146,000 units (SEC Form 4)

      4 - AbCellera Biologics Inc. (0001703057) (Issuer)

      3/7/25 3:32:01 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care

    $ABCL
    Financials

    Live finance-specific insights

    See more
    • AbCellera Reports Q1 2025 Business Results

      AbCellera (NASDAQ:ABCL) today announced financial results for the first quarter of 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "After completion of a successful first quarter, we are excited to introduce ABCL635 as a potential first-in-class antibody for the non-hormonal treatment of vasomotor symptoms (hot flashes) associated with menopause. ABCL635 is positioned as a next-generation neurokinin 3 receptor (NK3R) antagonist with an improved safety profile and convenient dosing regimen. If successful, we believe it has the potential to be a highly differentiated product in a large and established market," said Carl Hansen, P

      5/8/25 4:05:00 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

      AbCellera (NASDAQ:ABCL) will announce its first quarter 2025 financial results on Thursday, May 8, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's platform integrates technology, data

      4/3/25 4:05:00 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • AbCellera Reports Full Year 2024 Business Results

      AbCellera (NASDAQ:ABCL) today announced financial results for the full year 2024. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "In 2024 we made significant progress in transitioning from a platform company to a clinical-stage biotech, including advancing our internal pipeline and completing significant investments in our capabilities. We also maintained our strong cash position, closing the year with over $800 million in available liquidity to execute on our strategy," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "As a result, we enter 2025 on track to initiate Phase 1 clinical trials for our first two programs, ABCL635

      2/27/25 4:05:00 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care

    $ABCL
    SEC Filings

    See more
    • SEC Form 10-Q filed by AbCellera Biologics Inc.

      10-Q - AbCellera Biologics Inc. (0001703057) (Filer)

      5/8/25 4:21:37 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • AbCellera Biologics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - AbCellera Biologics Inc. (0001703057) (Filer)

      5/8/25 4:14:20 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form DEFA14A filed by AbCellera Biologics Inc.

      DEFA14A - AbCellera Biologics Inc. (0001703057) (Filer)

      4/29/25 4:37:17 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care

    $ABCL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • AbCellera Biologics downgraded by The Benchmark Company

      The Benchmark Company downgraded AbCellera Biologics from Buy to Hold

      8/20/24 6:47:45 AM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • AbCellera Biologics upgraded by The Benchmark Company with a new price target

      The Benchmark Company upgraded AbCellera Biologics from Hold to Buy and set a new price target of $9.00

      2/22/24 6:35:00 AM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • KeyBanc Capital Markets initiated coverage on AbCellera Biologics with a new price target

      KeyBanc Capital Markets initiated coverage of AbCellera Biologics with a rating of Overweight and set a new price target of $6.00

      12/5/23 7:12:21 AM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care

    $ABCL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Thermopylae Holdings Ltd. bought $742,243 worth of shares (343,631 units at $2.16), increasing direct ownership by 0.62% to 56,143,640 units (SEC Form 4)

      4 - AbCellera Biologics Inc. (0001703057) (Issuer)

      3/11/25 6:42:57 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • Director Montalbano John S. bought $57,500 worth of shares (25,000 units at $2.30), increasing direct ownership by 17% to 171,000 units (SEC Form 4)

      4 - AbCellera Biologics Inc. (0001703057) (Issuer)

      3/10/25 5:11:03 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • Director Montalbano John S. bought $140,568 worth of shares (60,000 units at $2.34), increasing direct ownership by 70% to 146,000 units (SEC Form 4)

      4 - AbCellera Biologics Inc. (0001703057) (Issuer)

      3/7/25 3:32:01 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care

    $ABCL
    Leadership Updates

    Live Leadership Updates

    See more
    • AbCellera Announces Resignation of Board Member

      AbCellera (NASDAQ:ABCL) today announced that Peter Thiel has notified the Company of his intention to resign from the Company's Board of Directors for personal reasons, effective March 7, 2024. "AbCellera continues to expand the frontier of biotech, a nefariously difficult and vital field," said Peter Thiel. "I am proud to have helped them with their mission." Mr. Thiel joined AbCellera's Board of Directors in November 2020 and served as the Chairman of the Company's Nominating and Corporate Governance Committee. Effective March 7, 2024, Dr. Andrew Lo, a member of the Company's Board of Directors, will be appointed to the Nominating and Corporate Governance Committee of the Board of Dir

      2/23/24 4:30:00 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • DAMONA Pharmaceuticals Appoints John Reilly as Chief Executive Officer

      TORONTO, June 13, 2023 /PRNewswire/ -- DAMONA Pharmaceuticals, a preclinical biopharmaceutical company focused on the discovery and development of first-in-class small molecules for the treatment and prevention of cognitive symptoms associated with brain disorders and aging, today announced the appointment of John Reilly as the company's Chief Executive Officer and member of the Board of Directors. Mr. Reilly brings two decades of leadership experience building and creating value for biotechnology companies, with deep knowledge and expertise in corporate strategy, business dev

      6/13/23 7:59:57 AM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • AbCellera Announces Changes to Its Board of Directors

      AbCellera (NASDAQ:ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced changes to its Board of Directors with the appointment of Andrew W. Lo, Ph.D., as an independent director and the resignation of John Hamer, Ph.D. Changes are effective immediately. Dr. Lo has developed new financial engineering tools and business models for drug and device development and healthcare delivery, statistical methods for incorporating patient preferences into the drug approval process, and machine-learning for predicting clinical trial outcomes. He will serve on the Audit and Compensation Committees of the Board of Directors. "Andrew is a d

      12/7/21 9:00:00 AM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care

    $ABCL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by AbCellera Biologics Inc.

      SC 13G/A - AbCellera Biologics Inc. (0001703057) (Subject)

      11/14/24 4:11:49 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form SC 13G filed by AbCellera Biologics Inc.

      SC 13G - AbCellera Biologics Inc. (0001703057) (Subject)

      2/14/24 4:21:54 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care
    • SEC Form SC 13G/A filed by AbCellera Biologics Inc. (Amendment)

      SC 13G/A - AbCellera Biologics Inc. (0001703057) (Subject)

      2/13/24 5:01:32 PM ET
      $ABCL
      Pharmaceuticals and Biotechnology
      Health Care